Loading…

Why LEMS Needs to be

Time is critical

LEMS is a progressive disorder—the longer an individual remains undiagnosed and untreated, the greater their burden of disease and the worse their quality of life.6

Patients with LEMS spent a mean of more than 4 years searching for an accurate diagnosis of their symptoms.1

It is estimated that approximately half the US LEMS population is currently undiagnosed.2

DIFFICULT TO DECIPHER

While some of the advanced signs of LEMS—such as severe muscle weakness1, unsteady gait5,6, and visual impairment1,3,4,7—can be easy to spot, deciphering the early signs of LEMS can be challenging for several reasons.

Slow disease progression2 causes some patients to delay seeking medical help

Nonspecific and fluctuating symptoms make LEMS difficult to recognize for both patients and physicians2

Common clinical presentation with other conditions leads to diagnostic confusion1,2

The Dossier On

LAMBERT-EATON MYASTHENIC SYNDROME (LEMS)

Declassified Information

  • Rare, immune-mediated disorder of the neuromuscular junction5
  • Causes debilitating and progressive muscle weakness and fatigue5,6
  • Progressive, leading to diminished physical functioning, quality of life, and independence6
  • Associated with small cell lung cancer (SCLC) in about 50% of cases2

Hallmark signs and symptoms7

See Details

HALLMARK SIGNS AND SYMPTOMS

Learn more about the distinguishing signs that can help you uncover LEMS in your practice.

Plus Icon
Plus Icon
Plus Icon
Plus Icon

DOWNLOAD YOUR

The signs of LEMS are out there; you just need the codes to decipher them—this is your guide. We’ve taken all the latest intel on LEMS and incorporated it here into one engaging resource.

Download it, read it, and join the mission to uncover undiagnosed LEMS.

Download

UNCOVER A PROVEN

The current standard of care for LEMS treatment is an oral therapy that works at the site of neuromuscular dysfunction to restore communication between the nerves and muscles.

Unlock LEMS Treatment

Goals for LEMS treatment include5,6,9,10:

  • Relief of autonomic symptoms
  • Maintenance/improvement in muscle strength and functional mobility
  • Maintenance/improvement in patient independence and quality of life
  • Screening/assessment for co-occurring cancer, particularly SCLC

READY FOR THE NEXT

Sign up to receive additional information about uncovering and managing LEMS in your practice.

Enter Your Information Below

*Required Fields

Request Contact
Catalyst Pharmaceuticals respects your personal information. The information you provide may be used to send you health-related materials and to develop products, services, and programs. Catalyst Pharmaceuticals or third parties working on our behalf will not sell or rent personal health information. Your information will only be used in accordance with the Catalyst Privacy Policy.

If you later wish to opt out of receiving this information, you may click on the unsubscribe link in future communications.

By completing this registration, you confirm that you are 18 years of age or older and a US resident.
This field is for validation purposes and should be left unchanged.

References:

  1. Merino-Ramírez MÁ, Bolton CF. Review of the diagnostic challenges of Lambert-Eaton syndrome revealed through three case reports. Can J Neurol Sci. 2016;43(5):635-647.
  2. Titulaer MJ, Lang B, Verschuuren JJGM. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098-1107.
  3. Young JD, Leavitt JA. Lambert-Eaton myasthenic syndrome: ocular signs and symptoms. J Neuroophthalmol. 2016;36(1):20-22.
  4. Titulaer JM, Wirtz PW, Wintzen AR, et al. Lambert-Eaton myasthenic syndrome with pure ocular weakness. Neurology. 2008;70(1):86-87.
  5. National Organization for Rare Disorders (NORD) website. Rare disease database: Lambert-Eaton myasthenic syndrome. Accessed July 25, 2024. https://rarediseases.org/rare-diseases/lambert-eaton-myasthenic-syndrome/.
  6. Harms L, Sieb J-P, Williams AE, et al. Long-term disease history, clinical symptoms, health status, and healthcare utilization in patients suffering from Lambert Eaton myasthenic syndrome: results of a patient interview survey in Germany. J Med Econ. 2012;15(3):521-530.
  7. Gordon LK. Paraneoplastic syndromes in neuro-ophthalmology. J Neuroophthalmol. 2015;35(3):306-314.
  8. National Health Service website. https://www.nhs.uk/conditions/lambert-eaton-myasthenic-syndrome/. Accessed August 18, 2022.
  9. Ivanovski T, Miralles F. Lambert-Eaton Myasthenic syndrome: early diagnosis is key. Degener Neurol Neuromuscul Dis. 2019;9:27-37.
  10. Quartel A, Turbeville S, Lounsbury D. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment. Curr Med Res Opin. 2010;26(6):1363-1375.